References
- Machado-Pinto J, Diniz MS, Bavoso NC. Psoriasis: new comorbidities. An Bras Dermatol 2016;91:8-16
- Evans C. Managed care aspects of psoriasis and psoriatic arthritis. Am J Manag Care 2016;22:S238-S43
- Hazard EH, Cherry SB, Lalla D, et al. The clinical and economic burden of psoriasis. Manag Care Interface 2006;19:20-6
- National Psoriasis Foundation. Psoriasis Fact Sheet. https://www.psoriasis.org/publications/patient-education/fact-sheets.
- Accessed November 2, 2016
- Enstilar Foam [package insert]. Parsippany, NJ: LEO Pharma Inc.; 2015
- Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris—a randomized phase III study (PSO-FAST). J Drugs Dermatol 2015;14:1468-77
- Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone and dipropionate aerosol foam vs ointment in patients with psoriasis vulgaris: a randomized phase II study. J Dermatol Treat 2016;27:120-7
- Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol 2016;9:34-41
- Queille-Roussel C, Olesen M, Villumsen J, et al. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig 2015;35:239-45
- Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol 2017;31:119-26
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59
- Van Voorhees AS, Feldman SR, Koo JYM, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. 4th ed. Portland, OR: National Psoriasis Foundation; 2016. p 1-134
- Paul C, Leonardi C, Menter A, et al. Calcipotriol plus betamethasone dipropionate aerosol foam is effective in patients with moderate-to-severe psoriasis: post-hoc analysis of the PSO-ABLE study. Poster presented at the 25th EADV Congress, September 28–October 2, 2016; Vienna, Austria.
- Feldman SR, Tencer T, Clancy Z, et al. Cost per responder of apremilast vs etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis. Presented at the 73rd Annual Meeting of the American Academy of Dermatology, March 20–24, 2015; San Francisco, CA
- Armstrong AW, Betts KA, Li J, et al. Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis. Poster presented at the 74th Annual Meeting of the American Academy of Dermatology, March 4–8, 2016, Washington, DC
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50